Respiratory Medicine
Volume 104, Issue 5 , Pages 758-759 , May 2010

Link between COPD and lung cancer

Received 28 October 2009

References 

  1. Potton E, Mc Caughan F, Janes S. Chronic obstructive pulmonary disease and lung cancer. Respir Med. 2009;5:34–37COPD Update
  2. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer independent of age, gender and smoking history. Eur Respir J. 2009;34:380–386
  3. Young RP, Hopkins R, Eaton TE. FEV1: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007;30:616–622
  4. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18(114):222–232
  5. Dasari V, Gallup M, Lemjabbar H, Maltseva I, Mc Namara N. Epithelial–mesenchymal transition in lung cancer: is tobacco the “smoking gun?”. Am J Respir Cell Mol Biol. 2006;35:3–9
  6. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-signaling. Am J Respir Cell Mol Biol. 2008;38:95–104
  7. Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, et al. Requirement for Rac1 in a K-ras-induced lung cancer in the mouse. Cancer Res. 2007;67:8089–8094
  8. Zondag GCM, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogene Ras down-regulates Rac activity, which leads to increased rho activity in epithelial-mesenchymal transition. J Cell Biol. 2000;149:775–782
  9. Barnes PJ, Celli BR. Systemic manifestations and co-morbidities of COPD. Eur Respir J. 2009;33:1165–1185
  10. Young RP, Hopkins RJ, Hay BJ, Epton MJ, Black PN, Gamble GD. Lung cancer gene associated with COPD: triple whammy or possible confounding effect?. Eur Respir J. 2008;32:1158–1164
  11. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med. 2009;103:1548–1553
  12. Dowlati A, Levitan N, Remick SC. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med. 1999;134:405–409
  13. Ancrile B, Lim K-H, Counter CM. Oncogenic Ras-induced secretion of IL-6 is required for tumorigenesis. Mol Interventions. 2008;8:22–27
  14. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, et al. Statins reduce interleukin-6 induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005;25:1231–1236
  15. Qu P, Roberts J, Li Y, Albrecht M, Cummings OW, Eble JN, et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and COPD. Lung Cancer. 2009;63:341–347
  16. Patel S, Mason RM, Suzuki J, Imaizumi A, Kamimura T, Zhang Z. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol. 2006;26:381–387

PII: S0954-6111(10)00052-1

doi: 10.1016/j.rmed.2009.11.025

Respiratory Medicine
Volume 104, Issue 5 , Pages 758-759 , May 2010

Article Tools

* Image Usage & Resolution